- en: All You Need to Know About the Non-Inferiority Hypothesis Test
  id: totrans-0
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 关于非劣性假设检验你需要知道的一切
- en: 原文：[https://towardsdatascience.com/all-you-need-to-know-about-non-inferiority-test-c58a74ec4cc5?source=collection_archive---------8-----------------------#2024-10-18](https://towardsdatascience.com/all-you-need-to-know-about-non-inferiority-test-c58a74ec4cc5?source=collection_archive---------8-----------------------#2024-10-18)
  id: totrans-1
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 原文：[https://towardsdatascience.com/all-you-need-to-know-about-non-inferiority-test-c58a74ec4cc5?source=collection_archive---------8-----------------------#2024-10-18](https://towardsdatascience.com/all-you-need-to-know-about-non-inferiority-test-c58a74ec4cc5?source=collection_archive---------8-----------------------#2024-10-18)
- en: A non-inferiority test statistically proves that a new treatment is not worse
    than the standard by more than a clinically acceptable margin
  id: totrans-2
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 非劣性检验通过统计方法证明新的治疗方法在临床可接受的范围内，不比标准治疗差
- en: '[](https://prateekkrjain.medium.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)[![Prateek
    Jain](../Images/aca13a91c244dcffc6a4971649af0ce8.png)](https://prateekkrjain.medium.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)[](https://towardsdatascience.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)[![Towards
    Data Science](../Images/a6ff2676ffcc0c7aad8aaf1d79379785.png)](https://towardsdatascience.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)
    [Prateek Jain](https://prateekkrjain.medium.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)'
  id: totrans-3
  prefs: []
  type: TYPE_NORMAL
  zh: '[](https://prateekkrjain.medium.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)[![Prateek
    Jain](../Images/aca13a91c244dcffc6a4971649af0ce8.png)](https://prateekkrjain.medium.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)[](https://towardsdatascience.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)[![Towards
    Data Science](../Images/a6ff2676ffcc0c7aad8aaf1d79379785.png)](https://towardsdatascience.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)
    [Prateek Jain](https://prateekkrjain.medium.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)'
- en: ·Published in [Towards Data Science](https://towardsdatascience.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)
    ·6 min read·Oct 18, 2024
  id: totrans-4
  prefs: []
  type: TYPE_NORMAL
  zh: ·发布于[Towards Data Science](https://towardsdatascience.com/?source=post_page---byline--c58a74ec4cc5--------------------------------)
    ·6分钟阅读·2024年10月18日
- en: --
  id: totrans-5
  prefs: []
  type: TYPE_NORMAL
  zh: --
- en: '![](../Images/59b1f94df176dbf50e72c65b6838f2d3.png)'
  id: totrans-6
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/59b1f94df176dbf50e72c65b6838f2d3.png)'
- en: Generated using Midjourney by [prateekkrjain.com](http://prateekkrjain.com)
  id: totrans-7
  prefs: []
  type: TYPE_NORMAL
  zh: 由[prateekkrjain.com](http://prateekkrjain.com)使用Midjourney生成
- en: While working on a recent problem, I encountered a familiar challenge — **“How
    can we determine if a new treatment or intervention is at least as effective as
    a standard treatment?”** At first glance, the solution seemed straightforward
    — just compare their averages, right? But as I dug deeper, I realised it wasn’t
    that simple. In many cases, the goal isn’t to prove that the new treatment is
    better, but to show that it’s *not worse* by more than a predefined margin.
  id: totrans-8
  prefs: []
  type: TYPE_NORMAL
  zh: 在处理一个最近的问题时，我遇到了一个熟悉的挑战——**“我们如何确定一种新的治疗或干预方法至少与标准治疗一样有效？”**乍一看，解决方案似乎很简单——直接比较它们的平均值，不是吗？但是当我深入研究时，我意识到事情并没有那么简单。在许多情况下，目标并不是证明新的治疗方法更好，而是要表明它*并不比标准治疗差*超过预定的边界。
- en: This is where **non-inferiority tests** come into play. These tests allow us
    to demonstrate that the new treatment or method is “not worse” than the control
    by more than a small, acceptable amount. Let’s take a deep dive into how to perform
    this test and, most importantly, how to interpret it under different scenarios.
  id: totrans-9
  prefs: []
  type: TYPE_NORMAL
  zh: 这就是**非劣性检验**发挥作用的地方。通过这些检验，我们可以证明新的治疗方法或方案在效果上“不比对照组差”超过一个小的、可接受的范围。让我们深入探讨如何执行这一检验，最重要的是如何在不同情境下解释它。
- en: The Concept of Non-Inferiority Testing
  id: totrans-10
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 非劣性检验的概念
- en: In non-inferiority testing, we’re not trying to prove that the new treatment
    is better than the existing one. Instead, we’re looking to show that the new treatment
    is **not unacceptably worse**. The threshold for what constitutes “unacceptably
    worse” is known as the **non-inferiority margin** (Δ). For example, if Δ=5, the
    new treatment can be up to 5 units worse than the standard treatment, and we’d
    still consider it acceptable.
  id: totrans-11
  prefs: []
  type: TYPE_NORMAL
  zh: 在非劣性检验中，我们并不试图证明新的治疗方法比现有方法更好。而是试图表明新的治疗方法**并不会明显更差**。所谓“明显更差”的阈值被称为**非劣性边界**（Δ）。例如，如果Δ=5，那么新的治疗方法可以比标准治疗差最多5个单位，仍然被认为是可接受的。
- en: This type of analysis is particularly useful when the new treatment might have
    other advantages, such as being cheaper, safer, or easier to administer.
  id: totrans-12
  prefs: []
  type: TYPE_NORMAL
  zh: 这种分析特别有用，尤其是在新的治疗方法可能具有其他优势的情况下，例如更便宜、更安全或更易于实施。
- en: Formulating the Hypotheses
  id: totrans-13
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 假设的制定
- en: 'Every non-inferiority test starts with formulating two hypotheses:'
  id: totrans-14
  prefs: []
  type: TYPE_NORMAL
  zh: 每个非劣效性检验都从提出两个假设开始：
- en: '**Null Hypothesis (H0​)**: The new treatment is worse than the standard treatment
    by more than the non-inferiority margin Δ.'
  id: totrans-15
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**零假设（H0）**：新治疗方法比标准治疗差超过非劣效性边界Δ。'
- en: '**Alternative Hypothesis (H1​)**: The new treatment is not worse than the standard
    treatment by more than Δ.'
  id: totrans-16
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**备择假设（H1）**：新治疗方法不比标准治疗差超过Δ。'
- en: 'When Higher Values Are Better:'
  id: totrans-17
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 当较高的值更好时：
- en: 'For example, when we are measuring something like drug efficacy, where **higher
    values are better**, the hypotheses would be:'
  id: totrans-18
  prefs: []
  type: TYPE_NORMAL
  zh: 例如，当我们测量药物效力时，**较高的值更好**，假设为：
- en: '**H0​**: The new treatment is worse than the standard treatment by at least
    Δ (i.e., μnew − μcontrol ≤ −Δ).'
  id: totrans-19
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**H0**：新治疗方法比标准治疗差至少Δ（即，μnew − μcontrol ≤ −Δ）。'
- en: '**H1​**: The new treatment is **not** worse than the standard treatment by
    more than Δ (i.e., μnew − μcontrol > −Δ).'
  id: totrans-20
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**H1**：新治疗方法不比标准治疗差超过Δ（即，μnew − μcontrol > −Δ）。'
- en: 'When Lower Values Are Better:'
  id: totrans-21
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 当较低的值更好时：
- en: 'On the other hand, when **lower values are better**, like when we are measuring
    side effects or error rates, the hypotheses are reversed:'
  id: totrans-22
  prefs: []
  type: TYPE_NORMAL
  zh: 另一方面，当**较低的值更好**时，例如当我们衡量副作用或错误率时，假设是反向的：
- en: '**H0**: The new treatment is worse than the standard treatment by at least
    Δ (i.e., μnew − μcontrol ≥ Δ).'
  id: totrans-23
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**H0**：新治疗方法比标准治疗差至少Δ（即，μnew − μcontrol ≥ Δ）。'
- en: '**H1​**: The new treatment is **not** worse than the standard treatment by
    more than Δ (i.e., μnew − μcontrol < Δ).'
  id: totrans-24
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**H1**：新治疗方法不比标准治疗差超过Δ（即，μnew − μcontrol < Δ）。'
- en: Z-Statistic
  id: totrans-25
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: Z统计量
- en: To perform a non-inferiority test, we calculate the **Z-statistic**, which measures
    how far the observed difference between treatments is from the non-inferiority
    margin. Depending on whether **higher or lower values are better**, the formula
    for the Z-statistic will differ.
  id: totrans-26
  prefs: []
  type: TYPE_NORMAL
  zh: 为了进行非劣效性检验，我们计算**Z统计量**，它衡量治疗之间观察到的差异与非劣效性边界的距离。根据**较高或较低的值更好**的情况，Z统计量的公式会有所不同。
- en: 'When **higher values are better**:'
  id: totrans-27
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: 当**较高的值更好**时：
- en: '![](../Images/008996de27836a2699e4af582d105b44.png)'
  id: totrans-28
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/008996de27836a2699e4af582d105b44.png)'
- en: 'When **lower values are better**:'
  id: totrans-29
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: 当**较低的值更好**时：
- en: '![](../Images/29ab6915089d2d249a21e2b115e1059c.png)'
  id: totrans-30
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/29ab6915089d2d249a21e2b115e1059c.png)'
- en: where δ is the observed difference in means between the new and standard treatments,
    and SE(δ) is the standard error of that difference.
  id: totrans-31
  prefs: []
  type: TYPE_NORMAL
  zh: 其中δ是新治疗与标准治疗之间的观察到的均值差异，SE(δ)是该差异的标准误差。
- en: Calculating P-Values
  id: totrans-32
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 计算P值
- en: 'The **p-value** tells us whether the observed difference between the new treatment
    and the control is statistically significant in the context of the non-inferiority
    margin. Here’s how it works in different scenarios:'
  id: totrans-33
  prefs: []
  type: TYPE_NORMAL
  zh: '**p值**告诉我们新治疗与对照组之间观察到的差异在非劣效性边界的背景下是否具有统计学意义。不同情境下的工作原理如下：'
- en: '**When higher values are better**, we calculate'
  id: totrans-34
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**当较高的值更好时**，我们计算'
- en: p = 1 − P(Z ≤ calculated Z)
  id: totrans-35
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: p = 1 − P(Z ≤ 计算得出的Z)
- en: as we are testing if the new treatment is not worse than the control (one-sided
    upper-tail test).
  id: totrans-36
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 因为我们正在检验新治疗是否不比对照组差（单边上尾检验）。
- en: '**When lower values are better**, we calculate'
  id: totrans-37
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**当较低的值更好时**，我们计算'
- en: p = P(Z ≤ calculated Z)
  id: totrans-38
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: p = P(Z ≤ 计算得出的Z)
- en: since we are testing whether the new treatment has lower (better) values than
    the control (one-sided lower-tail test).
  id: totrans-39
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 因为我们正在检验新治疗是否比对照组具有更低（更好）的值（单边下尾检验）。
- en: Understanding Confidence Intervals
  id: totrans-40
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 理解置信区间
- en: Along with the p-value, **confidence intervals** provide another key way to
    interpret the results of a non-inferiority test.
  id: totrans-41
  prefs: []
  type: TYPE_NORMAL
  zh: 除了p值，**置信区间**提供了另一种关键方式来解读非劣效性检验的结果。
- en: When **higher values are preferred**, we focus on the **lower bound** of the
    confidence interval. If it’s greater than −Δ, we conclude non-inferiority.
  id: totrans-42
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: 当**较高的值更受欢迎**时，我们关注置信区间的**下限**。如果它大于−Δ，我们就得出非劣效性结论。
- en: When **lower values are preferred**, we focus on the **upper bound** of the
    confidence interval. If it’s less than Δ, we conclude non-inferiority.
  id: totrans-43
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: 当**较低的值更受欢迎**时，我们关注置信区间的**上限**。如果它小于Δ，我们就得出非劣效性结论。
- en: '![](../Images/a0ed59a09bf5c0e251322069c9f151ce.png)'
  id: totrans-44
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/a0ed59a09bf5c0e251322069c9f151ce.png)'
- en: 'The confidence interval is calculated using the formula:'
  id: totrans-45
  prefs: []
  type: TYPE_NORMAL
  zh: 置信区间通过以下公式计算：
- en: '**when higher values preferred**'
  id: totrans-46
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**当较高的值更受欢迎时**'
- en: '![](../Images/1c93924d62d01194a4f9be3eb2b13342.png)'
  id: totrans-47
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/1c93924d62d01194a4f9be3eb2b13342.png)'
- en: '**when lower values preferred**'
  id: totrans-48
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**当较低的值更受欢迎时**'
- en: '![](../Images/79945d242cd4f366a787b44e3779a4bf.png)'
  id: totrans-49
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/79945d242cd4f366a787b44e3779a4bf.png)'
- en: Calculating the Standard Error (SE)
  id: totrans-50
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 计算标准误差（SE）
- en: The **standard error (SE)** measures the variability or precision of the estimated
    difference between the means of two groups, typically the new treatment and the
    control. It is a critical component in the calculation of the Z-statistic and
    the confidence interval in non-inferiority testing.
  id: totrans-51
  prefs: []
  type: TYPE_NORMAL
  zh: '**标准误差（SE）**衡量的是两个组之间均值差异估计值的变异性或精确度，通常是新治疗组与对照组之间的差异。这是计算Z统计量和置信区间在非劣效性检验中的关键组成部分。'
- en: 'To calculate the standard error for the difference in means between two independent
    groups, we use the following formula:'
  id: totrans-52
  prefs: []
  type: TYPE_NORMAL
  zh: 要计算两个独立组之间均值差异的标准误差，我们使用以下公式：
- en: '**between two means**'
  id: totrans-53
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**两个均值之间**'
- en: '![](../Images/56394ccf3fcc97646693433986efed91.png)'
  id: totrans-54
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/56394ccf3fcc97646693433986efed91.png)'
- en: '**between two proportions**'
  id: totrans-55
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**两个比例之间**'
- en: '![](../Images/d224246324d0d88892d1d921da1ef160.png)'
  id: totrans-56
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/d224246324d0d88892d1d921da1ef160.png)'
- en: 'Where:'
  id: totrans-57
  prefs: []
  type: TYPE_NORMAL
  zh: 其中：
- en: '**σ_new** and **σ_control** are the standard deviations of the new and control
    groups.'
  id: totrans-58
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**σ_new** 和 **σ_control** 分别是新治疗组和对照组的标准差。'
- en: '**p_new** and **p_control** are the proportion of success of the new and control
    groups.'
  id: totrans-59
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**p_new** 和 **p_control** 分别是新治疗组和对照组的成功比例。'
- en: '**n_new**​ and **n_control** are the sample sizes of the new and control groups.'
  id: totrans-60
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**n_new** 和 **n_control** 分别是新治疗组和对照组的样本大小。'
- en: The Role of Alpha (**α**)
  id: totrans-61
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: α（**α**）的作用
- en: In hypothesis testing, **α** (the significance level) determines the threshold
    for rejecting the null hypothesis. For most non-inferiority tests, **α=0.05**
    (5% significance level) is used.
  id: totrans-62
  prefs: []
  type: TYPE_NORMAL
  zh: 在假设检验中，**α**（显著性水平）决定了拒绝零假设的临界值。对于大多数非劣效性检验，使用**α=0.05**（5%的显著性水平）。
- en: A **one-sided test** with α=0.05 corresponds to a critical **Z-value of 1.645**.
    This value is crucial in determining whether to reject the null hypothesis.
  id: totrans-63
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**单侧检验**中，α=0.05对应一个临界**Z值为1.645**。这个值对于决定是否拒绝零假设至关重要。'
- en: The **confidence interval** is also based on this Z-value. For a 95% confidence
    interval, we use **1.645** as the multiplier in the confidence interval formula.
  id: totrans-64
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '**置信区间**也基于这个Z值。对于95%的置信区间，我们使用**1.645**作为置信区间公式中的乘数。'
- en: In simple terms, if your **Z-statistic** is greater than **1.645** for higher
    values, or less than **-1.645** for lower values, and the confidence interval
    bounds support non-inferiority, then you can confidently reject the null hypothesis
    and conclude that the new treatment is **non-inferior**.
  id: totrans-65
  prefs: []
  type: TYPE_NORMAL
  zh: 简单来说，如果你的**Z统计量**大于**1.645**（对于更高的数值），或者小于**-1.645**（对于更低的数值），且置信区间的界限支持非劣效性，那么你可以自信地拒绝零假设并得出结论，认为新治疗方法是**非劣效的**。
- en: Interpretation
  id: totrans-66
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 解释
- en: Let’s break down the interpretation of the **Z-statistic** and **confidence
    intervals** across four key scenarios, based on whether higher or lower values
    are preferred and whether the Z-statistic is positive or negative.
  id: totrans-67
  prefs: []
  type: TYPE_NORMAL
  zh: 让我们基于更高或更低的值是否更为理想以及Z统计量是正值还是负值，分四种关键情境来逐步解读**Z统计量**和**置信区间**。
- en: '**Here’s a 2x2 framework:**'
  id: totrans-68
  prefs: []
  type: TYPE_NORMAL
  zh: '**这是一个2x2框架：**'
- en: '![](../Images/4c150c7ad20852df31caa24a7c1d93ab.png)'
  id: totrans-69
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/4c150c7ad20852df31caa24a7c1d93ab.png)'
- en: Conclusion
  id: totrans-70
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 结论
- en: Non-inferiority tests are invaluable when you want to demonstrate that a new
    treatment is not significantly worse than an existing one. Understanding the nuances
    of Z-statistics, p-values, confidence intervals, and the role of α will help you
    confidently interpret your results. Whether higher or lower values are preferred,
    the framework we’ve discussed ensures that you can make clear, evidence-based
    conclusions about the effectiveness of your new treatment.
  id: totrans-71
  prefs: []
  type: TYPE_NORMAL
  zh: 非劣效性检验在你想证明一种新治疗方法不比现有治疗方法差时非常有价值。理解Z统计量、p值、置信区间以及α的作用将帮助你自信地解读结果。无论是更高还是更低的数值更为理想，我们所讨论的框架确保你能够对新治疗方法的有效性得出清晰、基于证据的结论。
- en: Now that you’re equipped with the knowledge of how to perform and interpret
    non-inferiority tests, you can apply these techniques to a wide range of real-world
    problems.
  id: totrans-72
  prefs: []
  type: TYPE_NORMAL
  zh: 现在，掌握了如何执行和解读非劣效性检验的知识后，你可以将这些技巧应用于各种现实世界中的问题。
- en: Happy testing!
  id: totrans-73
  prefs: []
  type: TYPE_NORMAL
  zh: 祝你测试愉快！
- en: '*Note: All images, unless otherwise noted, are by the author.*'
  id: totrans-74
  prefs: []
  type: TYPE_NORMAL
  zh: '*注：除非另有说明，所有图片均为作者提供。*'
